Report Highlights

Market Overview

South Korea is Northeast Asia's most commercially advanced NGS clinical diagnostics market outside Japan, combining a technically sophisticated hospital system, internationally competitive biotech industry, and an active national precision medicine programme. The country's NGS market has matured rapidly from research-only applications to clinical deployment across oncology, rare disease diagnosis, prenatal screening, and infectious disease genomics — a 5-year transition that reflects both the competitiveness of South Korean hospital procurement and the government's explicit support for genomics as a national biomedical industry priority.

The South Korean NGS market was valued at approximately USD 580 million in 2024, projected to reach USD 3.8 billion by 2034. Clinical diagnostics accounts for the largest and fastest-growing share, with NHI reimbursement of approved NGS panels for specific oncology indications driving hospital adoption of both platform instruments and diagnostic services. Macrogen, Theragen Bio, and Samsung Genome Institute are the dominant domestic providers, serving hospital laboratory, pharmaceutical research, and direct-to-consumer genomics segments.

South Korea's genomics industry has benefited from government-directed investment through the National Precision Medicine Initiative and the Korea Biobank Project (1 million participant cohort), creating a research infrastructure that supports commercial NGS application development. The country's strength in semiconductor manufacturing technology has created domestic interest in nanopore sequencing components and long-read sequencing technology development — a potential future competitive advantage in sequencing hardware that goes beyond the current instrument import dependency.

NHI reimbursement is the primary commercial lever: approved panel coverage for BRCA1/2, comprehensive cancer panel (CGP), and microsatellite instability (MSI) testing provides the revenue certainty that drives hospital NGS infrastructure investment. Reimbursement expansion to whole exome sequencing and liquid biopsy across broader oncology indications is the single most important market development variable for 2025–2028.

Key Growth Drivers

South Korea's National Health Insurance coverage of approved NGS panels for lung cancer, colorectal cancer, and hereditary cancer risk testing has created a direct clinical revenue model for hospital NGS laboratories and diagnostic service companies. Each reimbursement approval converts a research-use technology into a clinical standard-of-care — generating recurring diagnostic volume and justifying laboratory capital investment in NGS platforms. The pipeline of pending NHI approvals (liquid biopsy, comprehensive genomic profiling for additional tumour types, whole exome for rare disease) represents the primary growth catalyst: each new approval expands the addressable clinical NGS market by 15–30% for that indication category.

The Korean Genome Project (targeting 1 million participant whole genome sequences by 2028) and Korea Biobank Project create a research infrastructure foundation that supports commercial NGS application development — providing the reference genome and variant databases that diagnostic panels require for clinical interpretation. Government investment of KRW 200+ billion in genomics research infrastructure creates a talent pipeline, database resource, and research partnership ecosystem that commercial NGS companies leverage. The national cohort data also provides Korean-specific variant prevalence data that improves diagnostic accuracy for Korean patients beyond what Western reference databases provide.

South Korea's active pharmaceutical R&D sector — Samsung Biologics, Celltrion, Hanmi Pharmaceutical, and a growing biotech start-up ecosystem — generates companion diagnostic development demand that drives NGS platform adoption in clinical research and regulatory submission workflows. Companion diagnostic development for targeted therapies requires NGS-based biomarker assay development, regulatory validation, and post-approval monitoring that sustains laboratory NGS platform utilisation independent of clinical diagnostic reimbursement. The pharmaceutical-diagnostic partnership model (following the Roche-Foundation Medicine precedent) is emerging in South Korea through Samsung Genome Institute and Macrogen partnerships with domestic pharma companies.

Market Challenges

South Korea's NHI reimbursement approval process for new NGS indications takes 2–4 years from clinical evidence submission to approval — a timeline that creates a persistent gap between clinically validated NGS applications and commercially reimbursed applications. During this gap, clinical NGS adoption is limited to out-of-pocket patient payment or hospital-subsidised testing, constraining volume and slowing the adoption curve. The NHI evaluation criteria — which prioritise cost-effectiveness evidence over clinical utility — have been criticised by oncologists as creating unnecessarily high barriers for NGS diagnostics that have clear treatment decision value even when cost-effectiveness data is incomplete.

Clinical NGS deployment at hospital laboratories requires integration of NGS workflows (sample management, sequencing, bioinformatics) with hospital electronic medical record (EMR) systems and laboratory information systems (LIS). South Korean hospitals use a variety of EMR platforms (OCS, Bestcare, Asan Medical Centre proprietary systems) that require custom integration for NGS result reporting. This integration complexity adds 6–18 months to clinical NGS laboratory deployment timelines and requires bioinformatics and IT investment that smaller hospitals cannot afford without vendor support — creating a concentration of NGS clinical capability in large tertiary-care centres and slowing penetration into secondary hospitals.

Emerging Opportunities

Liquid biopsy — detecting circulating tumour DNA (ctDNA) in blood samples for early cancer detection, minimal residual disease monitoring, and treatment response assessment — is the highest-growth NGS application globally and a major opportunity for South Korean diagnostic companies. Korea's National Cancer Screening Programme (currently covering 5 cancer types via conventional methods) is a natural expansion target for multi-cancer early detection (MCED) liquid biopsy. Macrogen and Theragen Bio are developing Korean-specific ctDNA panels validated on the Korean Genome Project cohort, and NHI reimbursement submissions for liquid biopsy in specific high-incidence Korean cancer types (gastric, hepatocellular) are in preparation.

South Korea's NGS service providers — Macrogen, Theragen Bio, and Samsung Genome Institute — have established laboratory quality systems, clinical bioinformatics pipelines, and accreditation profiles (CAP, ISO 15189) that position them as export service providers to Southeast Asian and Middle Eastern hospitals lacking domestic NGS laboratory infrastructure. Macrogen already operates international sample collection networks in the US, Europe, and Asia. The 3–5 year opportunity is structured NGS diagnostic service agreements with hospitals in Indonesia, Vietnam, Saudi Arabia, and UAE — markets with growing cancer burden, no domestic NGS laboratory infrastructure, and premium healthcare sectors willing to pay for internationally accredited diagnostic quality.

Market at a Glance

Leading Market Participants

• Macrogen
• Theragen Bio
• Samsung Genome Institute
• Illumina Korea
• Bioneer Corporation

Regulatory and Policy Environment

South Korea's NGS regulatory framework is administered by the Ministry of Food and Drug Safety (MFDS) for diagnostic device approval and the National Health Insurance Service (NHIS) for reimbursement coverage. NGS-based in vitro diagnostics require MFDS approval under the Medical Device Act before clinical use — a process taking 12–24 months for novel panel-based assays. NHI reimbursement is evaluated separately by the Health Insurance Review and Assessment Service (HIRA), which assesses clinical utility and cost-effectiveness through a process independent of MFDS approval.

The 2020 amendment to the Bioethics and Safety Act governs research-use genomic data handling and consent requirements for Korean participants in genomic cohort studies. The Korea Biobank Act regulates the Korea Biobank Project data access framework, providing a structured pathway for commercial companies to access de-identified genomic data for diagnostic assay development. Personal data protection for genomic information falls under the Personal Information Protection Act (PIPA), with specific provisions for sensitive biometric and health data that NGS diagnostic companies must incorporate into laboratory information management system design.

Long-Term Outlook

By 2034, South Korea's NGS market will have reached USD 3.8 billion, with clinical diagnostics comprising 65–70% of revenue driven by NHI reimbursement expansion across comprehensive genomic profiling, liquid biopsy, and rare disease whole exome sequencing. Macrogen will have expanded its international presence significantly, with Asia-Pacific service revenue potentially exceeding domestic revenue — positioning it as a regional NGS service export champion.

South Korea's semiconductor manufacturing heritage is likely to produce a domestic contribution to sequencing hardware by 2034 — either through Samsung's entry into nanopore sequencing component manufacturing or through a start-up ecosystem developing novel sequencing chemistry leveraging Korean materials science and semiconductor process technology. This would diversify the NGS platform market beyond current Illumina dominance and create a domestic instrument manufacturing capability that none of the current major NGS markets possess.